NVTA NVTA インビティ

 NVTAのチャート


 NVTAの企業情報

symbol NVTA
会社名 Invitae Corp (NVTA インビティ)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インビタエ(Invitae Corporation)はデオキシリボ核酸(DNA)含有試料を処理し、患者固有の遺伝子変異に関する情報を分析し、臨床医およびその患者向けの試験報告書を生成するための、実験室プロセス、ソフトウェアツールおよび情報科学機能の統合ポートフォリオを利用する。同社の製品は、遺伝性がん、神経障害、心血管障害、小児障害およびその他の遺伝病を含む複数の適応症に使用できる1100以上の遺伝子を含むアッセイで構成される。同社はがん、心臓病、神経筋、小児および希少疾患における遺伝的条件についてパネルを提供する。同社は遺伝子検査、ゲノムネットワーク、ゲノム管理に重点を置く。同社は全ての試験の標準として完全な遺伝子シークエンシングおよび欠失・複製分析を提供している。同社は患者中心のデータ会社であるAltaVoiceに持分を有する。  インビティは、米国の遺伝子診断サ―ビス会社。病院や診療所などの医療機関に、遺伝子診断サ―ビスを提供する。遺伝性の乳がん、腸がん、前立腺がんなどの診断を目的とした遺伝子検査サ―ビスのほか、消費者向け遺伝子検査キットの開発・製造・販売も行う。本社は、カリフォルニア州サンフランシスコ。  Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
本社所在地 415 374-7782
代表者氏名 Randal W. Scott
代表者役職名 Executive Chairman of the Board
電話番号 +1 415-374-7782
設立年月日 40179
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 788人
url www.invitae.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) -109.05700
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 1978.53800
売上高 売上高(百万ドル) 147.69900
企業価値(EV) 企業価値(EV)(百万ドル) 1930.44200
当期純利益 当期純利益(百万ドル) -129.35500
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 InVitae Corp revenues increased from $68.2M to $147.7M. Net loss before extraordinary items increased 73% to $129.4M. Revenues reflect United States segment increase from $62.4M to $138.2M Rest of World segment increase from $2.5M to $5.3M. Higher net loss reflects Selling and Marketing - Balancing value increase of 41% to $69.5M (expense).

 NVTAのテクニカル分析


 NVTAのニュース

   Direct-to-consumer Genetic Testing Market Share and SWOT Analysis: Myriad Genetics Inc., 23andMe Inc., Invitae, Ambry Genetics  2020/11/16 14:09:16 OpenPR
The Direct-to-consumer Genetic Testing market report gives an in-depth analysis of the global market where it includes drivers, restraints, and trends, and opportunities contributing in the growth of the market. The Direct-to-consumer Genetic Testing report also consists of geographical analysis
   Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020  2020/11/05 21:05:00 PR Newswire
/PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter…
   Invitae Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2020/11/05 14:46:00 Stock Market Daily
Invitae announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening  2020/10/28 11:30:00 PR Newswire
— Three-quarters of patients with genetic changes had clinically relevant findings, including eligibility for precision therapies — SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human…
   Global Triple X Syndrome Treatment Market Projected To Show Strong Growth By 2027||Eurofins Scientific, Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer  2020/10/26 06:30:55 OpenPR
Triple X Syndrome is a rare genetic disorder characterized by chromosomal abnormality. It affects about 1 in 1000 females. The normal number of X chromosomes present in females in two but the person affected with triple X syndrome has three
   Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020  2020/11/05 21:05:00 PR Newswire
/PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter…
   Invitae Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2020/11/05 14:46:00 Stock Market Daily
Invitae announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening  2020/10/28 11:30:00 PR Newswire
— Three-quarters of patients with genetic changes had clinically relevant findings, including eligibility for precision therapies — SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human…
   Global Triple X Syndrome Treatment Market Projected To Show Strong Growth By 2027||Eurofins Scientific, Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer  2020/10/26 06:30:55 OpenPR
Triple X Syndrome is a rare genetic disorder characterized by chromosomal abnormality. It affects about 1 in 1000 females. The normal number of X chromosomes present in females in two but the person affected with triple X syndrome has three
   Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020  2020/10/23 11:30:00 PR Newswire
SAN FRANCISCO, Oct. 23, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m….

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 NVTA インビティ NVTA )

 twitter  (公式ツイッターやCEOツイッターなど)